

Cellular Uptake of PNA–Terpyridine Conjugates and Its Enhancement by Zn²⁺ Ions

Andreas Füssli,[†] Andreas Schleifenbaum,[‡] Mareike Göritz,[†] Andrew Riddell,[‡] Carsten Schultz,[‡] and Roland Krämer^{*,†}

Anorganisch-Chemisches Institut, Universität Heidelberg, Im Neuenheimer Feld 270, 69120 Heidelberg, Germany, and European Molecular Biology Laboratory (EMBL) Heidelberg, Meyerhofstrasse 1, 69117 Heidelberg, Germany

Received October 19, 2005; E-mail: roland.kraemer@urz.uni-heidelberg.de


Peptide nucleic acid (PNA) is a DNA mimic with a neutral pseudopeptide backbone.¹ It binds to complementary DNA with high affinity and specificity and displays high biological stability. As such, PNA is an ideal probe for monitoring gene expression on the cellular and molecular level, or it can be applied as an antisense and antigene reagent.

However, fast progress in the applications of PNA has been limited by its poor cellular uptake. Several noninvasive delivery strategies were developed: conjugation to oligopeptides with positively charged side chains,² to lipophilic molecules (adamantane,³ triphenylphosphonium,⁴ biotin⁵), to cell-specific receptor ligands,⁶ complexation with lipids and a DNA carrier,⁷ and backbone modification by introduction of a guanidinium group.⁸ Recent critical surveys⁹ point out the need for an extended repertoire of simple and effective cellular (and ultimately systemic) delivery methods to optimize performance of PNA-based probes or reagents in an application-dependent manner.

In an effort to control PNA activity chemically, we have recently developed a chelator-modified PNA¹⁰ that increases hybridization after activation with Zn²⁺, a metal with a high cell-type and tissue-specific distribution. Here we report that chemical modification of PNA by 2,2':6',2''-terpyridine (tpy) promotes cellular and nuclear uptake, which is further enhanced by Zn²⁺.

Solid-phase synthesis of PNAs 1–3 (Scheme 1) with randomly chosen sequences (9–20mer, no matching sequences in human genome database), tagged with a C-terminal fluorescent label and N-terminally attached tpy (1a–3a), is described in the Supporting Information.¹¹ Three C-terminal lysines were introduced to improve solubility and to facilitate attachment of fluorophores. For comparison, PNA 1c was prepared, with a C-terminal tetra-Lys tag and N-terminal rhodamine, but lacking tpy. PNA 1a was selected to study duplex stability with complementary DNA 4 (*T*_m = 50.1 °C). It is comparable to (Lys)₃-modified PNA of the same sequence (*T*_m = 47.8 °C). The fluorescence emission of PNA 1a with C-terminally attached dye (even when hybridized to DNA) was 8 times less intense than that of PNA 1c with the N-terminally attached dye. Reduced fluorescence is likely an effect of conversion of the dye's 2-carboxylic group to the piperidyl amide during PNA synthesis (Supporting Information).¹² Interestingly, PNAs 1a–3a behaved like “molecular beacons”,¹³ that is, fluorescence increased 3.3–7.0-fold upon hybridization with DNA (Figure 1). Apparently, tpy quenched rhodamine fluorescence, and the tpy–dye contact was disrupted on formation of the rigid PNA/DNA duplex. Fluorescence of 1a–3a was further reduced by addition of 1 equiv of Zn²⁺. Fluorescence of probes without tpy 1b–3b and 1c was minimally affected (0.8–1.2-fold, 1.6-fold for hybridization of 2b) by either hybridization or Zn²⁺ addition. Potentially, hybridization-enhanced

Scheme 1. Modified PNA Probes 1–3



PNA 1a (N) tpy-TCACAACtAk-Fl₁ (C); PNA 1b (N) TCACAACtAk-Fl₁ (C)
PNA 1a', 1a'' (N) tpy-TCACAACtAk-Fl_{1,33} (C)
PNA 1c (N) Fl₁-TCACAACtAk-k-k-k (C)
PNA 2a (N) tpy-TACACAACtK-Fl₁ (C); PNA 2b (N) TACACAACtK-Fl₁ (C)
PNA 3a (N) tpy-TCCTCGCCCTTGCTCACCAtk-Fl₁ (C)
PNA 3b (N) TCCTCGCCCTTGCTCACCAtk-Fl₁ (C)
Fl₁ = Tetramethylrhodamine, Fl₁ = Nile red, Fl₁ = Coumarin 343,
k = Lysine (C-terminal, Fl-modified Lys excluded)




Figure 1. Fluorescence of 1 μM PNA 1a–3a (red) ($\lambda_{\text{ex}} = 572$ nm, $\lambda_{\text{em}} = 593$ nm) in vitro is quenched upon addition of 1 equiv of Zn²⁺ (blue). Addition of 1 equiv of complementary DNA 4–6 opens the “molecular beacon”, and fluorescence is strongly increased (yellow); pH 7 (1 mM MOPS), 100 mM NaCl. DNA 4 5'-TAGTTGTGA-3', DNA 5 5'-AGT-TGTGA-3', DNA 6 5'-ATGGTGAGCAAGGGCGAGGA-3'.

fluorescence might be beneficial for the visualization of nucleic acid targets due to reduced background signaling.¹³

Uptake of PNAs 1–3 by HeLa cells was quantified by flow cytometry (Figure 2). Compared to 1b–3b, the tpy modification in 1a–3a increased cellular fluorescence 7.2–25.2-fold. Also, 1a entered cells much more effectively than tetra-Lys-PNA 1c, in particular, when taking into account the stronger fluorescence of the latter. A C-terminal tetra-Lys modification was reported to modestly improve cellular delivery of PNA and redirect gene splicing.¹⁴ Remarkably, in case of the PNA 9mers 1a and 2a (but not of the 20mer probe 3a), cellular fluorescence was 5.5 and 1.5-fold, respectively, higher in the presence of 1 equiv of Zn²⁺, indicating a significant enhancement of PNA uptake by Zn²⁺. This PNA sequence-dependent effect appears to be related to extracellular coordination of Zn²⁺ to the probe (Supporting Information, Figures

[†] Universität Heidelberg.
[‡] EMBL Heidelberg.




Figure 2. Flow cytometry analysis of HeLa cells incubated with 2.5 μM probe for 1 h. (a) Intensity counts for PNA **3b** + Zn^{2+} (green) and PNA **3a** + Zn^{2+} (red) (1 equiv of ZnSO_4). (b) Mean cellular fluorescence for various probes in the absence and presence of zinc ions, corrected for autofluorescence.

1s and 2s). It is unlikely in our view that such a complex, with the relatively weak Zn -chelator tpy (complex formation constant $\log K = 6$ for unmodified tpy),¹⁵ remains intact in a zinc-sequestering¹⁶ cytoplasmic environment. The tpy modification potentially enables selective cellular uptake of PNA by zinc-rich tissue (such as pancreas, testis, certain carcinoma, and the central nervous system) after stimulated zinc efflux from cells.¹⁷

Intracellular distribution of the probes in live HeLa cells was analyzed by confocal fluorescence microscopy, directly after incubation with 2 μM probe for 1 h (Figure 3). Typically, some fluorescence was observed in the cytoplasm, but nuclear staining was more pronounced. Both residual fluorescence (Figure 1) of the quenched probes and enhancement by nonspecific interactions (e.g., with proteins) might contribute to overall cellular fluorescence. Addition of Zn^{2+} did not seem to influence intracellular distribution of the probes. Analogues of **1a** in which the rhodamine fluorophore was replaced by coumarin ($\lambda_{\text{em}} = 494$ nm) and Nile Red ($\lambda_{\text{em}} = 655$ nm) also displayed efficient cellular and nuclear uptake (Supporting Information, Figure 3s). The lack of cellular import of **2a** at 4 $^\circ\text{C}$ may indicate an active cellular process.

In conclusion, the 2,2':6',2''-terpyridine (tpy) modification is readily introduced into PNA and efficiently promotes cellular and nuclear delivery. Zinc-enhanced cellular delivery is a first step toward a stimulus-controlled, tissue-selective uptake of PNA probes or reagents. Sequence-specific intracellular visualization of nucleic acid targets and the modulation of gene expression by tpy-PNA are under investigation.

Acknowledgment. We thank the Advanced Light Microscopy Facility and the Flow Cytometry Facility at EMBL for continuous




Figure 3. Confocal microscopy of living HeLa cells directly after incubation with 2 μM probe for 1 h (overlay DIC and rhodamine images). (a) PNA **2b** + Zn^{2+} ; (b) PNA **2a** + Zn^{2+} ; (c) PNA **2a**; (d) PNA **3a** + Zn^{2+} (1 equiv of ZnSO_4).

support. We thank H. Stichnot and U. Wildenberg for cultured cells, and S. Black for kindly providing Nile Red butyric acid pentafluorophenyl ester.

Supporting Information Available: PNA synthesis and characterization, T_m measurements of **1a**, flow cytometry (exp. details), UV titration of **1a** + Zn^{2+} , confocal microscopy of PNA **1a'**-**a''** intracellular distribution. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) Nielsen, P. E.; Egholm, M.; Berg, R. H.; Buchardt, O. *Science* **1991**, *254*, 1497–1500.
- (2) Simmons, C. G.; Pitts, A. E.; Mayfield, L. D.; Shay, J. W.; Corey, D. R. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 3001–3006.
- (3) Ljungstrom, T.; Knudsen, H.; Nielsen, P. E. *Bioconjugate Chem.* **1999**, *10*, 965–972.
- (4) Muratovska, A.; Lightowers, R. N.; Taylor, R. W.; Turnbull, D. M.; Smith, R. A.; Wilce, J. A.; Martin, S. W.; Murphy, M. P. *Nucleic Acids Res.* **2001**, *29*, 1852–1863.
- (5) Chinnery, P. F.; Taylor, R. W.; Diekert, K.; Lill, R.; Turnbull, D. M.; Lightowers, R. N. *Gene Ther.* **1999**, *6*, 1919–1928.
- (6) (a) Boffa, L. C.; Scarfi, S.; Mariani, M. R.; Damonte, G.; Allfrey, V. G.; Benati, U.; Morris, P. L. *Cancer Res.* **2000**, *60*, 2258–2262. (b) Zhang, X.; Simmons, C. G.; Corey, D. R. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 1269–1272.
- (7) Hamilton, S. E.; Simmons, C. G.; Kathariya, I.; Corey, D. R. *Chem. Biol.* **1999**, *6*, 343–351.
- (8) Zhou, P.; Wang, M.; Du, L.; Fischer, G. W.; Waggoner, A.; Ly, D. H. *J. Am. Chem. Soc.* **2003**, *125*, 6878–6879.
- (9) (a) Koppelhus, U.; Nielsen, P. E. *Adv. Drug Delivery Rev.* **2003**, *55*, 267–280. (b) Nielsen, P. E. *Gene Ther.* **2005**, *12*, 956–957.
- (10) Mokhir, A.; Krämer, R.; Wolf, H. *J. Am. Chem. Soc.* **2004**, *126*, 6208–6209.
- (11) Tpy-modified PNA is also described in: Kersebohn, T. (group of N. Metzler-Nolte), Doctoral Dissertation, University of Heidelberg, 2005.
- (12) Nguyen, T.; Francis, M. B. *Org. Lett.* **2003**, *5*, 3245–3248.
- (13) (a) Tyagi, S.; Kramer, F. R. *Nat. Biotechnol.* **1996**, *14*, 303–308. (b) Seitz, O. *Angew. Chem.* **2000**, *112*, 3389–3391.
- (14) Sazani, P.; Kang, S. H.; Maier, M. A.; Wei, C.; Dillmann, J.; Summerton, J.; Manoharan, M.; Kole, R. *Nucleic Acids Res.* **2001**, *29*, 3965–3974.
- (15) Holyer, R. H.; Hubbard, C. D.; Wilkins, R. C. *Inorg. Chem.* **1966**, *5*, 622–625.
- (16) Finney, L. A.; O'Halloran, T. V. *Science* **2003**, *300*, 931–936.
- (17) (a) Quian, W.; Gee, K. R.; Kennedy, R. *Anal. Chem.* **2003**, *75*, 3468–3475. (b) Luizzi, J. P.; Cousins, R. J. *Annu. Rev. Nutr.* **2004**, 24151–24172.

JA0571139